25th Anniversary Gala Celebration

Board Member Melissa Caito with Executive Director Peter “Quake” Pletcher

Founder Dr. R.M. Prasad Mantravadi (second from left) and family

Founder Dr. Patrick Loehrer, Sr., and long-time Advocate and Board Member, Ted Stansbury, going in for the real thing.

Chief Medical Officer Dr. Noah Hahn and wife

Founder Dr. Kenneth Pennington with daughter, Jennifer, who introduced him on stage,

Board Member Ted Stansbury with Keynote Speaker Merril Hoge

(l-r): Dr. Theresa Guise, Chairman Dr. Rafat Abonour, Treasurer Fuad Hammoudeh, and Secretary Dr. James Ruckle

Janie Gordon, cancer survivor and choir director of the 25th Street Singers, giving her inspirational message about the support of her friends and family

Peter “Quake” Pletcher (center) with IU basketball great Kent Benson and Purdue football great Leroy Keyes
Message from the Chairman .................. 2
Message from the Executive Director ..... 4
Our Leadership .................................. 6
25th Anniversary Retrospective ............... 10
New Partnerships for 2010 .................... 12
Advocacy Program ................................ 14
Advocate of the Year ............................ 16
Featured Researcher ............................. 18
Accomplishments ............................... 20
Our Community Reach ......................... 22
Our Financials ................................... 26
Our Supporters .................................. 30
The Hoosier Oncology Group is 25-years old. I see a great past and bright future. My days as Chairman are few and one has to acknowledge the trailblazers who laid this foundation. Their collaboration to defeat cancer was audacious, begun during an era of limited pipelines of active drugs and when the mechanism of cancer and drug therapy was vaguely understood. Despite that, practice changing trials were conducted successfully by the Hoosier Oncology Group. It is an honor to follow in the footsteps of leaders such as Pat Loehrer, Larry Einhorn, Rafat Ansari, Bill Fisher, Ken Pennington, and Prasad Mantravadi. Those Hoosier oncologists made it possible for us to know that we can make a difference by working together toward our hopeful vision.

Immediate Past Chair, Dr. Hanna, has transformed Hoosier Oncology into a modern organization while reaching out to people across Indiana and beyond, building a comprehensive clinical trial system that will address cancer down to the molecular level and bring novel agents into patients’ treatment options. Dr. Hanna will be a tough act to follow. We are happy that his talents will remain with us as he continues to serve as a Board Member and Chair of the Education Committee.

Where do I see Hoosier Oncology going in the next decade? Clinical research, like a human body, needs all the organs and parts to work in harmony. In Indiana, they all come together. The researchers at the Indiana University Melvin and Bren Simon Cancer Center (IUSCC), Purdue and Notre Dame will provide the ideas to be tested in clinical trials. The IUSCC and the Indiana Clinical Translational Science Institute (CTSI) will supply the tools needed to explore the mechanism of action and explain how drugs work on patients, a body of work called correlative studies. In addition, CTSI will facilitate patients’ engagement in clinical research. The oncologists across Indiana will supply ideas and clinical questions that need to be explored. The health care systems across Indiana will be a strong base for patient’s access to clinical trials. The role of our faculty as
members of the Indiana University Health system and Indiana University Health Physicians will lead to a more coordinated flow of patients into clinical trials. Hoosier Oncology will be the heart of this body. It will be the circulatory system that ensures that each component of this complex body of clinical research is working in harmony to achieve our ultimate goal of eradicating cancer.

Finally, I am grateful to serve with and on behalf of those who make all this possible. First, I thank the Hoosier Oncology Group family, led by Quake Pletcher. Quake and his talented team have been working hard to make clinical research available to all Hoosiers. They rise meet the challenges of today’s research climate and warrant a sincere thank you. But foremost in my heart is my appreciation for the patients who face cancer. I continue to be in awe whenever I interact with a patient who is facing an uncertain future. I always learn from these encounters that the human spirit is never about fear, despair, or surrender. Cancer patients are brave, hopeful, and selfless. They embrace clinical research because they want to better themselves and, more admirably, to serve the rest of humanity by finding a cure for cancer. Thank you for being the trailblazers and leaders on the path to a cure by participating in clinical research.

With gratitude,

Rafat
Chairman, Hoosier Oncology Group

Rafat Abonour, M.D., Chairman, Hoosier Oncology Group
“By Jove, I am not covetous for gold,
Nor care I who doth feed upon my cost;
It yearns me not if men my garments wear;
Such outward things dwell not in my desires.
But if it be a sin to covet honour,
I am the most offending soul alive...

We few, we happy few, we band of brothers;
For he to-day that sheds his blood with me
Shall be my brother; be he ne’er so vile,
This day shall gentle his condition;
And gentlemen in England now-a-bed
Shall think themselves accurs’d they were not here,
And hold their manhoods cheap whiles any speaks
That fought with us upon Saint Crispin’s day.”

Shakespeare, St. Crispin’s Day Speech

This year we were fortunate to celebrate 25 years of cancer research at the Hoosier Oncology Group. We watched as our founders embraced on stage at the Scottish Rite Cathedral in April. This “band of brothers” labored and laughed for a quarter of a century in collegial debate and impassioned care delivery in support of cancer research innovation. In this serious business of cancer research, we saw that levity and optimism about future cures make the Hoosier Oncology Group a special club.

But it is more than that. We are about believing and achieving.

We believe we have the capacity to ease the burden of cancer on our friends and family members. We do not stop until our research achieves the change in clinical practice that delivers those results. This is what sets us apart as guardians of good research - good research—this unflinching conviction that a clinical trial today is the cure for tomorrow...and it had better be a Hoosier Oncology study!
We move forward, thriving and invigorated, with those core values of what membership in this distinguished club means. In fact, it’s attracted many outsiders who share the same simple values of hard work, hospitality, and humility. And in applying those values, ultimately we achieve our mission. I always marvel at what our research community does ... the healing touch our caregivers deliver to patients, the courage of patients to walk boldly into a study with the highest stakes, the dedication of our researchers who pour over the latest ever-changing scientific literature no matter the time of day to spark that next innovation, that next cure. The faint-hearted and weak-minded need not apply to this club. Membership, as they say, is not for everybody. There is absolutely nothing in this environment to suggest that cancer research is getting easier, and we have the team who will endure where others fall short.

We are well positioned to carry forward the legacy our foundational leadership provided. It is an honor to serve our Hoosier Oncology research community – because the collective soul is so worthy of it.

We are asking the right questions. We are operating the right way. And the green shoots of succession are taking root. I look forward to our Golden Anniversary where we honor the next wave of club leadership, the “band of brothers and sisters,” who have waged the battles against cancer and won.

With fondness and sincerity,

Peter “Quake” Pletcher
Executive Director, Hoosier Oncology Group
Board Leadership
& Key Thought Leaders

HOOSIER ONCOLOGY GROUP, INC.

Rafat Abonour, M.D., Chairman, Associate Dean of Clinical Research, Indiana University School of Medicine; Director of the Adult Clinical Research Office, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Wael Harb, M.D., Chief Community Officer, Medical Director and Medical Oncologist, Horizon Oncology Center, Lafayette, IN

James Ruckle, Ph.D., Secretary, President and CEO, Walther Cancer Foundation, Indianapolis, IN

Fuad Hammoudeh, Treasurer, Administrator of Cancer Programs, Clarian Health, Indianapolis, IN

Noah Hahn, M.D., Chief Medical Officer, Assistant Professor of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Members At Large
Bilal Ansari, M.D.
Sumeet Bhatia, M.D.
Melissa Caito
Christopher LeMasters
Timothy Ratliff, Ph.D.
John Salter, M.D.
Bryan Schneider, M.D.
Ted Stansbury

Board Emeritus
Rafat Ansari, M.D.
Lawrence Einhorn, M.D.
William Fisher, M.D.
Patrick Loehr, M.D.
R.M. Prasad Mantravadi, M.D.
Lawrence Einhorn, M.D.
Distinguished Professor of Medicine; Lance Armstrong Professor of Medicine, Indiana University School of Medicine

Dr. Einhorn is a founding father of Hoosier Oncology Group and served as chief medical officer for many years. Dr. Einhorn is a world-recognized leader in the treatment of testicular cancer, with Lance Armstrong as one of his many successfully treated patients. Dr. Einhorn’s other area of specialization is solid tumors within genitourinary and lung cancers.

Patrick Loehrer Sr., M.D.
Director, Indiana University Melvin and Bren Simon Cancer Center; H.H. Gregg Professor of Oncology; Associate Dean for Cancer Research, Indiana University School of Medicine

Dr. Loehrer is a founding father of Hoosier Oncology Group and served as Chairman from inception in 1985 until 2005. Under his direction, Hoosier Oncology grew from an idea among a group of physicians into the world-class organization it is today. Dr. Loehrer is a world-recognized leader in the treatment of thymoma and thymic malignancies. His other areas of specialization include bladder, testis, pancreatic and colon cancers.

George Sledge Jr., M.D.
Ballve-Lantero Professor and Professor in the Departments of Hematology/Oncology and Pathology and Laboratory Medicine, Indiana University School of Medicine; President, American Society of Clinical Oncology

Dr. Sledge has been a Hoosier Oncology Group researcher for more than 20 years, playing numerous roles in the development of Hoosier Oncology research. Most recently, Dr. Sledge serves as principal investigator for all the Center of Excellence for Individualization of Therapy for Breast Cancer studies, which are multi-year, multi-protocol Department of Defense funded studies.

Timothy Ratliff, Ph.D.
Director of the Purdue Cancer Center; Professor of Comparative Pathobiology, Department of Comparative Pathobiology, School of Veterinary Medicine, Purdue University

As a member of the board of directors and a Clinical Trials Working Group, Dr. Ratliff lends his basic science expertise in the development of research studies. His personal research focuses on immunotherapy of prostate and bladder cancers, the communication between innate and adaptive immune compartments via platelets and prostate and bladder inflammation.
Rafat Abonour, M.D.
Chairman, Hoosier Oncology Group; Associate Dean of Clinical Research, Indiana University School of Medicine; Director of the Adult Clinical Research Office, Indiana University Melvin and Bren Simon Cancer Center
Dr. Abonour provides guidance to Hoosier Oncology Group research initiatives and business plans through his role as chairman. Beyond his clinical practice, which specializes in myelomas, Dr. Abonour created a non-profit organization called Miles for Myeloma, an annual event he and his patients created to generate research funds for this rare blood cancer.

Charles Buck, Ph.D.
Director of Operations, Bindley Bioscience Center in Discovery Park, Purdue University
Dr. Buck has been the director of operations for the Bindley Bioscience Center (BBC) at Purdue University’s Discovery Park since December 2004. His research expertise is in the molecular biology of vertebrate nervous system development and response to injury, as well as in human liver diseases and cancer. Dr. Buck serves as the Hoosier Oncology Group bioinformatics, tissue collection and biorepository consultant in the development of protocols to leverage the science of proteomics in cancer research.

Elena Gabriela (Gabi) Chiorean, M.D.
Assistant Professor of Medicine, Indiana University School of Medicine
Dr. Chiorean is an oncologist specializing in GI cancers. Her research focus is to develop novel, phase I/pilot trials and clinically study the influence of various molecular markers in cancer genesis and implement cancer prevention strategies. Dr. Chiorean also has an interest in translational work and collaborations with other disciplines, such as radiology, GI medicine, pharmacogenomics, molecular biology and radiation oncology.

Sherif Farag, M.B.B.S., Ph.D.
Associate Professor, Indiana University School of Medicine; Director, Bone Marrow & Stem Cell Transplantation Program, Associate; Director for Clinical Research, Indiana University Melvin and Bren Simon Cancer Center
Dr. Farag’s research focus is on the development of novel approaches to hematopoietic stem cell transplantation, including safer approaches to alternate donor transplantation. He also is focused on the development of novel agents and regimens for the treatment of multiple myeloma, including pre-clinical research of new drug development.
Noah Hahn, M.D.
Chief Medical Officer, Hoosier Oncology Group; Assistant Professor of Medicine, Indiana University School of Medicine

As Chief Medical Officer, Dr. Hahn provides leadership and expertise in the development of Hoosier Oncology Group research. Dr. Hahn’s personal research focuses on both prostate and bladder cancers and the signatures that identify healthy men at risk of developing clinically aggressive lethal prostate cancer. In addition, Dr. Hahn is interested in the environmental factors that damage DNA and attribute to cancers.

Nasser Hanna, M.D.
Immediate Past Chair, Hoosier Oncology Group; Associate Professor of Medicine at Indiana University School of Medicine

As past chairman, Dr. Hanna brings to the Hoosier Oncology Group proven leadership in addition to his landmark research in the area of lung and thoracic cancers. His research interests include various aspects of lung cancer research, including areas of epidermal growth factor receptor inhibition, anti-angiogenesis, cell-cycle inhibitors, and novel chemotherapeutic agents.

Daniela Matei, M.D.
Associate Professor of Medicine, Biochemistry, Obstetrics and Gynecology, Indiana University School of Medicine

Dr. Matei’s research interest is in the area of ovarian cancer and the role of the platelet derived growth factor pathway in cancer progression, gene expression analysis, and novel biomarkers.

Kathy Miller, M.D.
Associate Professor and Sheila D. Ward Scholar, Indiana University School of Medicine

Dr. Miller specializes in breast cancer with a special interest in new cancer treatments, including clinical trials of biologically based therapies. She is the principal investigator on the novel PARP Inhibitor study which opened in 2010 and the clinical core investigator on the multi-year Department of Defense funded study for the Center of Excellence for Individualization of Therapy for Breast Cancer.

Bryan Schneider, M.D.
Assistant Professor, Indiana University School of Medicine

Dr. Schneider’s research focus is in the translational sciences, particularly in the area of breast cancer. In his own lab, Dr. Schneider hopes to identify critical genetic and pharmacogenetic differences that predict etiology, aggressiveness, and therapeutic responsiveness as it relates to cancer.
A Night to Remember
25th Anniversary Gala Event

Hoosier Oncology proudly celebrated 25 years of ground-breaking cancer research with an elegant gala event honoring our founding fathers, Drs. Rafat Ansari, Lawrence Einhorn, William Fisher, Patrick Loehrer Sr., R.M. Prasad Mantravadi, and Kenneth Pennington.

Keynote speaker Merril Hoge brought a powerful message that resonated with the crowd. As an unlikely 8-year NFL player and a cancer survivor, he shared his inspiring personal commitment to sustained excellence and always “finding a way” to meet our respective goals.

Mary Jean Wasielewski (left with Dr. William B. Fisher) was a very deserving recipient of a special Sandra Turner Award for her 25 years of service in support of research. She started her walk in cancer research at the Northern Indiana Cancer Research Consortium (NICRC) alongside Sandra.

In addition to many touching moments, moving words and awards to several who have had outstanding service and advocation, Janie Gordon, choir director and cancer survivor, spoke about how the support from family and friends was like a “Bridge Over Troubled Water.” A moving rendition of that song was sung by the Columbus North High School Choir, 25th Street Singers, while a video of In-Memory and In-Honor of loved ones played.
“The gala celebrating our 25-year anniversary was profoundly meaningful to me in two ways....a look back at our early days and our hopes in the beginning, and a challenge to the new generation of oncology teams to grow and expand the dream.”

William B. Fisher, M.D., one of the founding fathers of Hoosier Oncology Group, Clinical Professor of Medicine at Indiana University and Co-Director of Cancer Services at Ball Memorial Hospital.
New Partnerships for 2010 and Beyond

Hoosier Oncology Group was founded by Indiana University and community oncologists with the idea of bringing academic research and clinical trials to hometown healthcare.

Since its inception, Hoosier Oncology has partnered with Indiana University in every aspect of clinical research, from study development to presenting our research findings at prestigious oncology meetings.

Now, 25 years later, Indiana University Melvin and Bren Simon Cancer Center signed a Memo of Understanding with the Hoosier Oncology Group, formally aligning our research objectives. The Hoosier Oncology Group is now the community clinical outreach arm of the IU Simon Cancer Center.

Hoosier Oncology Group is grateful to have a friend in IU Simon Cancer Center and we look forward to another 25 years of meaningful research.

One exciting new partnership is with the Mayo Clinic Cancer Research Consortium, which will broaden the depth of our research into other states, towns and clinics.

"Both Hoosier Oncology Group and Mayo Clinic Cancer Research Consortium strive to provide promising cancer therapeutics to patients in their own communities and have strong alliances between high quality academic institutions and community practices."

Jan Buckner, M.D., Chair, Mayo Clinic Cancer Research Consortium; Professor of Oncology, and Chair, Division of Medical Oncology, Mayo Clinic
In Honor and In Memory of our Loved Ones

In Honor of Don Russell, oral cancer survivor

In Memory of Judy Heimberger, pancreatic cancer

In Memory of Phyllis Newcomb, colorectal cancer

In Memory of Pauline and John Waffle

In Memory of Harry "Ike" Pletcher, prostate cancer survivor

In Memory of Judy Heimberger, pancreatic cancer

In Memory of Marjorie Williams

In Memory of Shawn Hamilton

In Memory of Isalene Wilson, liver cancer

In Memory of Jack Weiss (right), esophageal cancer

In Memory of Jack Weiss (right), esophageal cancer

In Memory of Paula Marie Kendrick

In Memory of Marjorie Williams

In Memory of John Waffle

In Memory of Jack Weiss (right), esophageal cancer

In Memory of Isalene Wilson, liver cancer

In Memory of Harry "Ike" Pletcher, prostate cancer survivor

In Memory of Paula Marie Kendrick

In Honor of James M. Hamilton

In Honor of Krysti Hughett, breast cancer survivor

In Honor of Manuel Morales

In Memory of James M. Hamilton

In Honor of Anne Garber

In Memory of Marjorie Williams

In Memory of Judy Heimberger, pancreatic cancer

In Memory of Phyllis Newcomb, colorectal cancer

In Memory of Pauline and John Waffle

In Memory of Harry "Ike" Pletcher, prostate cancer survivor

In Memory of Paula Marie Kendrick

In Memory of Isalene Wilson, liver cancer

In Memory of Jack Weiss (right), esophageal cancer

In Memory of Paula Marie Kendrick

In Honor of Anne Garber

In Memory of Manuel Morales

In Memory of James M. Hamilton

In Honor of Krysti Hughett, breast cancer survivor

In Honor of Anne Garber
Advocacy Program: Research Is the Answer

One of the most exciting initiatives to come to fruition this year is the Hoosier Oncology Advocacy Program (HOAP). The purpose of the Advocacy Program is to provide the patient perspective to the research being conducted within the Hoosier Oncology Group and to educate the public on the importance of clinical cancer research.

Many cancer patients or their loved ones become involved in advocacy after their own experience as a clinical trial participant. Advocates play several important roles, such as consulting on study design, reviewing consents and protocols, speaking about clinical trials, and providing support to cancer patients.

OUTCOMES
The Research Advocates completed a pilot program where trained volunteers were asked to review protocols and suggest changes. More than six studies were reviewed in the pilot. After review, 41 percent of the recommend changes for the Informed Consent were made, and 56 percent of recommend changes for the Protocol were made. Overall, one costly amendment was avoided because of our volunteers efforts!

![Protocol Type of Changes](chart)

- **Conflict**
- **Convenience**
- **Accrual**
- **Safety Understanding**
- **Amendment Avoidance**

**Win!**

<table>
<thead>
<tr>
<th>Protocol Type of Changes</th>
<th>Changed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conflict</td>
<td>2</td>
</tr>
<tr>
<td>Convenience</td>
<td>2</td>
</tr>
<tr>
<td>Accrual</td>
<td>6</td>
</tr>
<tr>
<td>Safety Understanding</td>
<td>4</td>
</tr>
<tr>
<td>Amendment Avoidance</td>
<td>1</td>
</tr>
</tbody>
</table>
“Working with the Hoosier Oncology Group community research sites has been a wonderful and inspiring experience. The advocates are so enthusiastic and full of ideas and believe this is a way of giving back to other cancer patients and to the researchers that had such a significant influence on their treatment and their lives.”

Mary Lou Smith, Co-Founder of Research Advocacy Network, breast cancer survivor and long-time advocate
Advocate of the Year

Nasir Ghiaseddin, Ph.D., had been a professor of Information Systems at the University of Notre Dame for more than 23 years when he was diagnosed with gastric cancer in December 2005.

He underwent surgery, followed by chemo and radiation therapy. When Dr. Ghiaseddin’s oncologist offered him a choice between standard treatment or treatment through a clinical trial, he said, “For me the choice was obvious. If everyone opts out of clinical trials, how should the new drugs and treatment methodologies be tested? If not me who else?” Hence, he started treatment under the clinical trial CALGB 80101 protocol.

Since his own cancer journey, Dr. Ghiaseddin has been a staunch advocate of clinical trial research and a true friend to Hoosier Oncology. He has been an active member of the Hoosier Oncology Advocacy Program (HOAP) and participated in the Hoosier Oncology awareness videos developed to educate patients on the importance of Hoosier Oncology’s mission to bring leading cancer treatments to hometown healthcare.

When asked how he became interested in research advocacy, Ghiaseddin responded, “NCI reports that the five-year survival rate in 2001 was 68.3 percent and the goal was to reach at 70 percent survival rate in 2010. The question is: Are we satisfied with this number? What about the other 30 percent? How can we increase the survival rate to a more respectable number? The answer is: More research is needed.”
Dr. Ghiaseddin commented on why he chose to advocate for Hoosier Oncology: “From a patient advocate’s point of view, it is very important that [Hoosier Oncology] recruits local sites for research so patients in local sites can participate in clinical trials without traveling to larger cities.”

At the 25th anniversary gala in April 2010, Honorary Co-Chair Jane Hoeppner presented the Terry Hoeppner Patient Advocacy Award to Dr. Ghiassedin for his great research advocacy on study design and legislation.

Hoosier Oncology is extremely fortunate to have such friends and advocates like Dr. Ghiaseddin.

“If there is only one organization that one wants to support in the State of Indiana for cancer research, it should be the Hoosier Oncology Group.”

Nasir Ghiaseddin, Ph.D., Advocate of the Year
Hoosier Oncology acknowledges Elena Gabriela (Gabi) Chiorean M.D., for her continued contributions to Hoosier Oncology cancer research this year.

Dr. Chiorean is a young, up-and-coming superstar in the area of metastatic colorectal and pancreatic cancers at the Indiana University Melvin and Bren Simon Cancer Center.

“Dr. Chiorean is down-to-earth. She is easy to work with and always makes time to talk to a site or a researcher about a protocol,” says Colleen Currie, Project Manager at the Hoosier Oncology Group offices.

Chiorean’s current and future projects relate to novel therapeutics for refractory colorectal cancer, as well as enhancing the value of current pancreatic cancer chemotherapies with the addition of targeted agents that prevent DNA repair, in a collaborative effort with laboratory scientists at Indiana University.

When asked about her experience working with Hoosier Oncology, Dr. Chiorean comments, “My work with the [Hoosier Oncology Group] has brought to fruition many exciting projects, but all of it is due to the amazing people that span hands-on clinical staff to translational and biomarker research specialists. This collaboration brings together academic and community practices which puts the patients’ needs and the intellectual curiosity side-by-side to fulfill quality research.”
In Honor of Coach Hep and in honor of his “Don’t Quit” attitude

In Memory of Sandra Turner, whose mission lives on in the annual Sandra Turner Award

God had a good day when he decided to put wisdom, humility and friendship in one package. He called it Steve Williams.

In Memory of Katie Vogelgesang
In Memory of Mary Ellen Hughbanks Alerding
In Honor of Ruth Vogelgesang

In Memory of all the patients that take part in clinical trials, no matter what crazy things we ask of them! (put this on... sit in this tent)

In Honor of Karen Borkowsky Kennedy, breast cancer survivor

Bill Arnold, prostate cancer Survivor

In Honor of Jenny Goggin, breast cancer survivor

In Memory of Tammy Hapgood

In Honor of Dave Tyndall

In Memory of Robert Finch

In Honor of Ted Stansbury (left) and Arnold Palmer (center)

In Honor of Kathy Peters
Accomplishments

Hoosier Oncology is proud of our accomplishments and impact on cancer research over the past year. We have broadened our community outreach, increased the number of studies opened, and accrued hundreds of patients to our studies.

- Opened 16 new clinical research sites
- Opened 6 studies

Tremendous strides were made in the areas of operational efficiency, by decreasing the time from study concept to the first patient treated by 50 percent, and increased our accrual rates.

Cycle times for protocol development reduced 50%

Accrual rates up 10% on a normalized basis
Published Manuscripts


Daniela Matei, Jeanne Schilder, Gregory Sutton, Susan Perkins, Tim Breen, Check Quon, Carolyn Sidor. Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial, Gynecologic Oncology 115 (2009) 90–96. PMID: 19577796 (Hoosier Oncology Study number GYN06-106)


Abstracts


A Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination with a 5HT3 Antagonist and Dexamethasone in Patients with Germ Cell Tumors Undergoing 5-day Cisplatin-Based Chemotherapy Regimens. A Hoosier Oncology Group Study (H.O.G.). M.J. Brames, E. Johnston, C.R. Nichols, J. Picus, D.J. Vaughn, C.A. Fausel, T.E. Breen, M. Yu, and L.H. Einhorn; Indiana University Simon Cancer Center and Indiana University School of Medicine, Division of Biostatistics, Indianapolis, IN, Providence Cancer Center, Portland, OR, Washington University Siteman Cancer Center, St. Louis, MO, and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA. Multinational Association of Supportive Care in Cancer (MASCC) Meeting 2010

American Society of Clinical Oncology 2010 Meeting

Noah Hahn, M.D., and his team presented the mature results of GU04-75 as a poster discussion titled, "A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC)."

Daniela Matei, M.D., and her team presented findings for GYN-111 abstract titled, "A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis," which was presented as part of the scientific program in the general poster session.

Nagesh Jayaram, M.D., and his team also presented findings in the general poster session for the abstract titled, "The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: a subset analysis of HOG LUN01-24/USO-023."

Christopher Sweeney, M.B.B.S., and his team's submission of GU02-41 titled, "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy" was published.
Our Community Reach Is Far and Wide

Our partnerships with the many academic and community cancer clinics across the United States enable oncologists to participate in meaningful cancer research while providing cutting-edge treatment to patients in their own communities.

**Arizona**
Mayo Clinic Cancer Center, Phoenix

**Arkansas**
Highlands Oncology Group, Fayetteville

**Delaware**
Christiana Care, Helen F. Graham Cancer Center, Newark

**Florida**
Shand Cancer Center, University of Florida, Gainesville

**Georgia**
Emory University, Atlanta

**Illinois**
Ingalls Memorial Hospital, Harvey
Kellogg Cancer Care Center, NorthShore University Health System, Evanston
Medical & Surgical Specialists, LLC, Galesburg
Northwestern University Feinberg School of Medicine, Chicago
Rush-Presbyterian, Chicago
The University of Chicago, Chicago

**Indiana**
Arnett Cancer Care, Lafayette
Cancer Care Center of S Indiana, Bloomington
Cancer Care Center, Inc., New Albany
Central Indiana Cancer Centers, Indianapolis
Community Regional Cancer Center, Indianapolis
Evansville Multi-Specialty Clinic, Evansville
Ft. Wayne Medical Oncology & Hematology, Ft. Wayne
Good Samaritan Hospital, Vincennes
Horizon Oncology Center, Lafayette
Indiana Oncology Hematology Consultants, Indianapolis
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Jasper Memorial Hospital, Jasper
Medical Consultants, P.C., Muncie
Monroe Medical Associates, Munster
Northern Indiana Cancer Research Consortium, South Bend
Oncology Hematology Associates of SW Indiana, Newburgh
Parkview Research Center, Fort Wayne
Providence Medical Group, Terre Haute
South Bend Clinic, South Bend
St. Vincent Gynecologic Oncology, Indianapolis
St. Vincent Hospitals, Indianapolis
Louisiana
Louisiana State University Health System, Leonard J. Chabert Medical Center, Houma

Massachusetts
Dana Farber Cancer Institute, Boston

Missouri
Washington University School of Medicine, St. Louis

Nebraska
Methodist Cancer Center, Omaha
University of Nebraska Medical Center, Omaha

New Jersey
Hunterdon Regional Cancer Center (Fox Chase), Flemington
Southern Oncology-Hematology Associates (Fox Chase), Vineland
Virtua Fox Chase Cancer Program

New York
Schwartz Gynecologic Oncology, PLLC, Brightwaters

Ohio
University Hospitals Case Medical Center, Ireland Cancer Center, Cleveland

Oregon
Oregon Health and Science University, Portland
Providence Portland Medical Center, Portland

Pennsylvania
Fox Chase Cancer Center, Philadelphia
Grandview Hospital (Fox Chase), Sellersville
Pennsylvania Oncology Hematology Associates (Fox Chase), Philadelphia
PinnacleHealth Regional Cancer Center (Fox Chase), Harrisburg
Reading Hospital Regional Cancer (Fox Chase), Reading
University of Pennsylvania, Philadelphia

South Carolina
Medical University of South Carolina, Spartanburg
Spartanburg Regional Healthcare System, Spartanburg

Tennessee
The West Clinic (ACORN), Memphis
Our Community Reach Is Far and Wide (Continued)

**Texas**
- Baylor College of Medicine - Methodist Breast Center, Houston
- CTRC at the UT Health Science Center at San Antonio
- Texas Oncology PA, Sammons Cancer Center, Austin
- The Methodist Hospital, Houston
- University of Texas Southwestern Medical Center, Dallas

**Virginia**
- Virginia Oncology Associates, Newport News

**Wisconsin**
- Medical College of Wisconsin, Milwaukee

**INTERNATIONAL SITES**

**Peru**
- Instituto de Enfermedades Neoplasticas (INEN), Lima

**Poland**
- Medical University of Gdansk (Poland), Gdansk

**United Kingdom**
- St. Barts and The London School, London
Why Community Partners Are So Important

Average Distance to Test Site = 41 miles

Average Distance to IU Simon Cancer Center = 80 miles

Total Distance Saved = 1.7 million miles

Gas Money Saved = $215,000

Our mission is clear: bring the best available cancer treatments to the local clinics.

If a patient lived in Columbus, Ind., instead of driving up to Indianapolis to the IU Simon Cancer Center, they could drive to Bloomington.

This translates into great savings of time and money and allows patients to receive treatment near their support group, with less disruption to daily activities.
Report of Independent Auditors

To the Board of Directors
Hoosier Oncology Group, Inc.
Indianapolis, Indiana

We have audited the accompanying statements of financial position of the Hoosier Oncology Group, Inc. (the “Organization”) as of June 30, 2010 and 2009 and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Organization’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Hoosier Oncology Group, Inc. as of June 30, 2010 and 2009, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Our audits were made for the purpose of forming an opinion on the basic financial statements taken as a whole. The schedules of functional expenses are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

Crowe Horwath LLP

Indianapolis, Indiana
November 30, 2010
## Hoosier Oncology Group, Inc.

**Statements of Financial Position**  
**June 30, 2010, and 2009**

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalent</td>
<td>$2,222,629</td>
<td>$2,777,917</td>
</tr>
<tr>
<td>Accounts and grants receivable, net</td>
<td>1,478,169</td>
<td>915,276</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>71,108</td>
<td>65,548</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>24,593</td>
<td>69,181</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$3,796,499</td>
<td>$3,827,922</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$209,091</td>
<td>$278,953</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>230,148</td>
<td>117,562</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>51,928</td>
<td>42,364</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>23,599</td>
<td>225,388</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>514,766</td>
<td>664,267</td>
</tr>
</tbody>
</table>

| Net assets       |                 |                 |
| Unrestricted     | 3,099,115       | 3,041,155       |
| Temporarily restricted | 182,618   | 122,500         |
| **Total net assets** | 3,281,733   | 3,163,655       |

| **Total liabilities and net assets** | $3,796,499 | $3,827,922 |
Hoosier Oncology Group, Inc.

Statement of Activities
Year ended June 30, 2010 (with summary total for the year ended June 30, 2009)

<table>
<thead>
<tr>
<th></th>
<th>Temporarily</th>
<th>Restricted</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>External support - research</td>
<td>$ 2,890,320</td>
<td>$ -</td>
<td>$ 2,890,320</td>
<td>$ 1,960,062</td>
</tr>
<tr>
<td>Federal research grants</td>
<td>236,267</td>
<td>$ -</td>
<td>236,267</td>
<td>406,683</td>
</tr>
<tr>
<td>Contributions and other grant support</td>
<td>198,506</td>
<td>60,118</td>
<td>258,624</td>
<td>80,587</td>
</tr>
<tr>
<td>Interest income</td>
<td>13,889</td>
<td>$ -</td>
<td>13,889</td>
<td>33,537</td>
</tr>
<tr>
<td>Special Events</td>
<td>103,557</td>
<td>$ -</td>
<td>103,557</td>
<td>45,283</td>
</tr>
<tr>
<td>Other income</td>
<td>69,861</td>
<td>$ -</td>
<td>69,861</td>
<td>42,230</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td>3,512,400</td>
<td>60,118</td>
<td>3,572,518</td>
<td>2,568,382</td>
</tr>
</tbody>
</table>

|                      |             |            |          |          |
| **Expenses**         |             |            |          |          |
| Program services     |             |            |          |          |
| Investigator initiated research | 1,790,122 | $ -        | 1,790,122 | 1,620,113 |
| Industry research    | 223,508     | $ -        | 223,508  | 369,022 |
| Government research  | 632,489     | $ -        | 632,489  | 599,903 |
| **Total program services** | 2,646,119 | $ -        | 2,646,119 | 2,589,038 |
| Supporting services  |             |            |          |          |
| Administration       | 658,973     | $ -        | 658,973  | 485,822 |
| Fundraising          | 149,348     | $ -        | 149,348  | 122,119 |
| **Total supporting services** | 808,321 | $ -        | 808,321  | 607,941 |
| **Total expenses**   | 3,454,440   | $ -        | 3,454,440 | 3,196,979 |

| **Change in net assets** | 57,960 | 60,118 | 118,078 | (628,597) |

| **Net assets, beginning of year** | 3,041,155 | 122,500 | 3,163,655 | 3,792,252 |

| **Net assets, end of year** | $ 3,099,115 | $ 182,618 | $ 3,281,733 | $ 3,163,655 |

Hoosier Oncology Group | Annual Report
Hoosier Oncology Group, Inc.

Statement of Cashflow
Years ended June 30, 2010, and 2009

<table>
<thead>
<tr>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$ 118,078</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash used from operating activities:</td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>60,783</td>
</tr>
<tr>
<td>Change in assets and liabilities:</td>
<td></td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>(562,893)</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>-</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>(5,560)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(69,862)</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>112,586</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>9,564</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(201,789)</td>
</tr>
<tr>
<td><strong>Net cash provided by (used in) operating activities</strong></td>
<td>(539,093)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from investing activities</strong></td>
<td></td>
</tr>
<tr>
<td>Purchase of property and equipment</td>
<td>(16,195)</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(16,195)</td>
</tr>
<tr>
<td><strong>Net change in cash and cash equivalents</strong></td>
<td>(555,288)</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>2,777,917</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at end of year</strong></td>
<td>$ 2,222,629</td>
</tr>
</tbody>
</table>


Thank You to Our Supporters

The Hoosier Oncology Group wishes to thank all those who contributed throughout the year to our mission of providing cutting-edge research to people within their community.

We are so fortunate to have many friends and supporters who give of their time, money, services, expertise and other valuable resources to help us fulfill our mission.

It is our hope that through their continued generosity, and through the generosity of others, that future generations may not know the pain of cancer.

Our Contributors*

PLATINUM  ($5000 and above)

Clarian Health
Dr. Wael Harb, Horizon Oncology Center
Ice Miller, LLC
Indiana University
Michiana Hematology-Oncology
Ted Stansbury

SILVER  ($800 - $2499)

Joanna Arnold
Ball Memorial Hospital
Dr. Sumeet and Sumeeta Bhatia
Melissa Caito
John Fisher
Dr. Noah Hahn
Dr. Nasser Hanna
Christopher LeMasters
Dr. Mary Lou Mayer
Medical Consultants, PC
Phillip Pletcher

GOLD  ($2500 - $4999)

Ansari Family Foundation
Philip Caito
Community Hospitals Oncology Practice
Crowe Horwath, LLP
Tracey Day, Southern Roofing
Dr. William B. Fisher
Rick Johnson, Johnson Ventures, Inc.
Dr. Kenneth Kesler, Cardio Thoracic Surgeons
Dr. R.M. Prasad Mantravadi
Mickey Mauer, The National Bank of Indianapolis
Memorial Hospital, South Bend
Peter Quake Pletcher
Purdue University
Stephen and Livia Russell
St. Vincent Hospitals
Dr. Robin Zon
The Hoosier Oncology Group strives to acknowledge each and every contributor accurately. The information above reflects contributions made between July 1, 2009-June 30, 2010. If the information listed above is incorrect or not inclusive, please contact our offices at 317-921-2050 and ask for Deb Cole. Thank you for your support!

The Hoosier Oncology Group also wishes to thank all the dedicated investigators, clinical research site personnel and, most importantly, the patients who make our research possible.

How You Can Help

You can make a tax-deductible donation toward our mission online:


If you are interested in volunteering or becoming an advocate, visit our Volunteer webpage at:

www.hoosieroncologygroup.org/Volunteer-ops.aspx